Compare Hasbro, Inc. (HAS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs BIO-TECHNE Corp — how do they compare? Hasbro, Inc. trades at $92.82 (market cap $13.05B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Hasbro, Inc. and BIO-TECHNE Corp are close in size by market cap, and Hasbro, Inc. pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and BIO-TECHNE Corp for 63 Days on average.
| HAS | TECH | |
|---|---|---|
Market Cap | $13.05B | $11.36B |
Volume | 1,207,655 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $72.61 |
52-Week Low | $70.95 | $43.31 |
Typical Hold Time | 97 Days | 63 Days |
Enterprise Value | $15.24B | $11.39B |
Dividend Yield | 3.03% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $90.75, down 0.31% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates robust profitability with 64.41% gross margins and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains positive with a $107.60 price target, representing 18.5% upside potential from current levels. Recent news highlights continued momentum in the Magic: The Gathering franchise and new product collaborations.
The outlook remains constructive with projected revenue growth to $5.0B in 2026 and net income recovery to $794M. Key risks include high debt levels at 59.09% debt-to-asset ratio and recent net income volatility. The stock offers value with reasonable P/E of 16.14x and strong institutional interest, though investors should monitor Q3 2026 earnings on October 20 for confirmation of the turnaround trajectory.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
